RxDoctor Payments Data

Vartan Yeghiazarians, MD

Internal Medicine · Methuen, MANPI 1134130735

Payments from drug & device makers

$1,167in general payments, 2019–2025

Across 36 payments — averaging $32.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$322
  • Astellas Pharma US Inc$237
  • Abbott$226
  • Lilly USA, LLC$84
  • Novo Nordisk$79
  • GSK$65
  • plus $155 from 5 others

What the payments were for

  • Food & beverage$1,06891%
  • Education$1009%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,167 in reported general payments places this provider in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$497,665
Medicare patients
770
Services billed
8,855

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban244$264,146
MounjaroTirzepatide125$178,123
Trelegy ElliptaFluticasone/Umeclidin/Vilanter144$172,280
JardianceEmpagliflozin112$144,906
TrulicityDulaglutide82$123,399
XareltoRivaroxaban36$48,946
FarxigaDapagliflozin Propanediol28$44,427
WegovySemaglutide26$34,772
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$26,618
OzempicSemaglutide25$23,510
Tresiba Flextouch U-200Insulin Degludec13$16,301
OxycontinOxycodone Hcl13$15,986
KonvomepOmeprazole/Sodium Bicarbonate11$15,485
Rosuvastatin Calcium380$10,536
Atorvastatin Calcium777$10,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$84$301,522207 claims
PfizerEliquis$57$264,146244 claims
GSKTrelegy Ellipta$65$172,280144 claims
Novo NordiskWegovy, Ozempic$79$58,28251 claims
AstraZenecaFarxiga$322$44,42728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Methuen

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →